CRISPR Therapeutics AG reported first quarter 2026 results: revenue $43 million.
“CASGEVY generated first quarter 2026 revenue of $43 million.”
CRISPR Therapeutics AG — fact timeline
Source-grounded facts extracted from CRISPR Therapeutics AG's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).
“On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)”
CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.
“On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)”
CRISPR Therapeutics AG: Shareholders approved amendments to the Articles of Association, as described in the Proxy Statement, effective upon registration in the Commercial Register in Zug, Switzerland on or about June 6, 2025 (effective 2025-06-06).
“On June 5, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved amendments to the articles of association of the Company (the “Articles of Association”) as described in the Company’s proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 16, 2025 (the “Proxy Statement”).”
Julianne Bruno resigned as Chief Operating Officer at CRISPR Therapeutics AG.
“On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.”
Julianne Bruno was appointed as Chief Operating Officer at CRISPR Therapeutics AG.
“On May 23, 2024, CRISPR Therapeutics AG (the “Company”) announced the promotion of Julianne Bruno, currently the Company’s Senior Vice President and Head of Programs & Portfolio, to be the Company’s Chief Operating Officer effective as of May 23, 2024.”
CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2024.
“On May 8, 2024, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.